Literature DB >> 8069569

Use of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers.

T J Raub1, C L Barsuhn, L R Williams, D E Decker, G A Sawada, N F Ho.   

Abstract

The novel antioxidants U-78517F and U-74006F, or lazaroids, are highly lipophilic organic molecules with poor brain uptake. To understand this paradoxical behavior better, continuous monolayers of Madin-Darby canine kidney (MDCK) epithelial cells with distinct apical (AP) and basolateral (BL) plasma membrane domains grown on polycarbonate membrane filters and plastic were used to examine the mechanism of transcellular diffusion. Independent kinetic experiments were used to quantify AP to BL flux, efflux from the AP and BL membranes and AP membrane partitioning as functions of bovine serum albumin (BSA) concentration. Fluxes were appropriately reduced to permeability coefficients (Pe) for the membrane, aqueous boundary layer (ABL) and filter, BSA-drug binding constants, and effective (Ke) and intrinsic (Kintr) membrane partition coefficients in the absence of metabolism. Both Pe and Ke decreased exponentially with increased BSA concentration and a concomitant decrease in free drug concentration. Uptake was ABL-controlled under the conditions used and its Pe was 1,000-fold faster than that for efflux due to a large Kintr. Therefore, diffusion across the cellular barrier was limited kinetically by the equilibrium between protein-bound drug and free drug partitioned into the cell membrane and the rate-limiting desorption of drug from the cell membrane into the aqueous receiver. This suggests that brain uptake of these lipophilic antioxidants is limited by interactions with plasma proteins and, possibly, by unfavorable partitioning from the endothelium into the underlying tissue. The present biophysical kinetic model is proposed as generally useful in studying the penetrative ability of other membrane interacting molecules.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8069569     DOI: 10.3109/10611869308996085

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  11 in total

1.  Transepithelial transport of bepridil in the human intestinal cell line, Caco-2, using a "dynamic model".

Authors:  F Mathieu; M J Galmier; A Nicolay; J F Pognat; C Lartigue
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Apr-Jun       Impact factor: 2.441

2.  A novel strategy for physiologically based predictions of human pharmacokinetics.

Authors:  Hannah M Jones; Neil Parrott; Karin Jorga; Thierry Lavé
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 3.  The far-reaching scope of neuroinflammation after traumatic brain injury.

Authors:  Dennis W Simon; Mandy J McGeachy; Hülya Bayır; Robert S B Clark; David J Loane; Patrick M Kochanek
Journal:  Nat Rev Neurol       Date:  2017-02-10       Impact factor: 42.937

4.  Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers.

Authors:  S D Raeissi; I J Hidalgo; J Segura-Aguilar; P Artursson
Journal:  Pharm Res       Date:  1999-05       Impact factor: 4.200

5.  The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds.

Authors:  B J Aungst; N H Nguyen; J P Bulgarelli; K Oates-Lenz
Journal:  Pharm Res       Date:  2000-10       Impact factor: 4.200

6.  Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells.

Authors:  Sibylle Neuhoff; Per Artursson; Ismael Zamora; Anna-Lena Ungell
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.200

7.  Effects of inclusion complexation on the transepithelial transport of a lipophilic substance in vitro.

Authors:  M J Cho; F J Chen; D L Huczek
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

Review 8.  Pharmacology of traumatic brain injury: where is the "golden bullet"?

Authors:  Kathryn Beauchamp; Haitham Mutlak; Wade R Smith; Esther Shohami; Philip F Stahel
Journal:  Mol Med       Date:  2008-08-18       Impact factor: 6.354

9.  Transcellular permeability of chlorpromazine demonstrating the roles of protein binding and membrane partitioning.

Authors:  G A Sawada; N F Ho; L R Williams; C L Barsuhn; T J Raub
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

Review 10.  How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?

Authors:  Kazutoshi Watanabe; Masahiko Tanaka; Satoshi Yuki; Manabu Hirai; Yorihiro Yamamoto
Journal:  J Clin Biochem Nutr       Date:  2017-11-11       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.